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Risk for rheumatic disease in relation to ethnicity and admixture
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Abstract
Risk of systemic lupus erythematosus (SLE) is high in west Africans compared with
Europeans, and risk of rheumatoid arthritis (RA) is high in Native Americans compared with
Europeans. These differences are not accounted for by differences in allele or haplotype
frequencies in the human leucocyte antigen (HLA) region or any other loci known to
influence risk of rheumatic disease. Where there has been admixture between two or more
ethnic groups that differ in risk of disease, studies of the relationship of disease risk to
proportionate admixture can help to distinguish between genetic and environmental
explanations for ethnic differences in disease risk and to map the genes underlying these
differences.
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Introduction
The risks of developing SLE and RA vary with ethnic
origin. Prevalence of lupus has been found to be up to
eight times higher in African-American and Afro-Caribbean
populations than in people of European descent. The con-
sistency with which high prevalence of lupus occurs in
populations of west African descent who are living in dif-
ferent environments suggests that genetic factors are
likely to underlie the high risk in this group. The high risk
for lupus in west Africans compared with in Europeans
does not appear to be accounted for by differences in
allele frequencies at any of the loci at which associations
with SLE have been found, including those in the HLA
region. Other populations at high risk for lupus include
Pacific islanders and Chinese-Americans, with prevalence
rates up to three times higher than in people of European
descent living in the same countries. For RA, the highest
risks are recorded for Native American populations, in
which prevalence is up to four times higher than it is in
Europeans. Although the frequency of alleles that code for
the high-risk ‘shared epitope’ at the HLA-DRB1 locus is
higher in Native Americans than in Europeans, this only
accounts for a population risk ratio of about 1.4, com-
pared with the observed risk ratios of around 4.
Where there has been admixture between ethnic groups
that differ in risk for disease, studies of how the risk for
disease varies with proportionate admixture can help to
distinguish between genetic and environmental explana-
tions for the difference in disease risk and can help to
define the genetic model. No adequate studies have yet
been undertaken on the risk for lupus in relation to admix-
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ture in populations of mixed European/west African
descent, or on the risk for RA in relation to admixture in
populations of mixed European/Native American descent.
If ethnic differences in risk for lupus and RA have a
genetic basis, it is possible in principle to map the genes
that underlie ethnic differences in risk by studying affected
individuals of mixed descent. This approach is an exten-
sion of the methods used for linkage analysis of a cross in
experimental genetics. Before this can be applied in prac-
tice, it is necessary to assemble sets of marker polymor-
phisms that can be used to assign ancestry on
chromosomes of mixed descent.
Ethnic variation in risk for rheumatic disease
Studying ethnic variation in disease risk can yield clues to
environmental or genetic factors that influence disease risk.
Where variations in risk between populations have been
identified, studies of migrants between low-risk and high-
risk areas can help to distinguish between genetic and
environmental explanations for these differences in risk,
and to determine the age at which risk is set. If an ethnic
difference in disease risk has an environmental explanation,
this difference is expected to ‘wear off’ within a few genera-
tions after migration [1]. For instance, the low risk for multi-
ple sclerosis in tropical countries compared with the risk in
northern latitudes persists in those who migrate from tropi-
cal countries to the UK as adults [2], but in second-genera-
tion migrants the risk for multiple sclerosis is similar to that
in the host population [3]. If, on the other hand, genetic
factors underlie an ethnic difference in disease risk, we
would expect this ethnic difference to persist in popula-
tions where migrants have been settled overseas for many
generations, and to be observed consistently in all coun-
tries where a given migrant group has settled.
Ethnic variation in risk for systemic lupus erythematosus
Most estimates of SLE prevalence have relied on ascer-
tainment of cases already diagnosed. A study in the UK
that used a questionnaire followed by an antinuclear anti-
body test to screen for undiagnosed cases of SLE [4]
suggested that about 40% of cases are undiagnosed.
Estimates of the risk ratio for SLE in one ethnic group
compared with another generally assume that the propor-
tion of cases that are undiagnosed and the average sur-
vival of diagnosed cases are the same in both groups. If
these assumptions hold, the risk ratio can be estimated
from the ratio of prevalence rates of diagnosed SLE in the
two groups. The assumption that the proportion of cases
that are undiagnosed does not vary between ethnic
groups is more likely to hold in the UK, where access to
health care does not depend on income, than in the USA.
Table 1 summarizes prevalence studies in populations of
west African descent, with prevalence in populations of
European descent in the same countries for comparison.
In general, the prevalence of SLE has been found to be far
higher in people of west African descent settled in Europe
and the Americas than in Europeans [5,6]. In the UK,
prevalence in adults is estimated to be around 35 per
100 000 in women of European descent [5,7], compared
with 200–250 per 100 000 in women of Afro-Caribbean
origin [5,6].
It has been suggested that rates of SLE are low in west
African because exposure to malaria and parasitic infec-
tions in west Africans in the tropics may result in an
altered immunological state, leading to a tolerance of host
antigens or absorption of autoantibody [8]. However, there
are no population-based data on prevalence of SLE in
west Africa itself.
Similar risk ratios have been reported in studies performed
in the USA [9,10] that have compared prevalence rates in
African-Americans and European-Americans. In a study of
patients registered with the Kaiser Foundation Health Plan
in San Francisco, age-adjusted prevalence of SLE in
African-American women aged over 15 years was esti-
mated to be 375 per 100 000, compared with 81 per
100 000 for European-American women [9]. The relatively
high prevalence rates in this study may be attributable to
the unrestricted access to health care. In other studies
from the USA, coverage of the population by the health
care system is likely to vary considerably between ethnic
Table 1
Prevalence of systemic lupus erythematosus in European, Afro-Caribbean and African American women
Location Ethnicity Age range Age-standardized prevalence/100 000
Birmingham, UK [6] European ≥18 years 36
Birmingham, UK [6] Afro-Caribbean ≥18 years 197
Nottingham, UK [5] Afro-Caribbean ≥20 years 251
Curacao, West Indies [12] Afro-Caribbean (predominantly) ≥15 years 117
San Francisco, USA [9] African-American ≥15 years 375
San Francisco, USA [9] European-American ≥15 years 81
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groups. If poorer access to health care results in a lower
proportion of cases ascertained in African-Americans, and
shorter survival among diagnosed cases, this would
reduce the ratio of prevalence in African-Americans to that
in European-Americans. The incidence of SLE was esti-
mated to be four times higher in African-American than in
European-American women [10], which is approximately
the same as the ratio recorded in studies that compared
prevalence rates. From the studies that are available at
present, it is not possible to establish whether the differ-
ence between the risk ratios of 6–8 reported in the UK
and the risk ratios of 4–5 reported in the USA are real or
attributable to differences in the extent to which the risk
ratios are biased by differential case ascertainment. In
most African-American populations the proportion of Euro-
pean admixture varies from 14 to 22%. Most Afro-
Caribbean migrants to the UK are from Jamaica, where the
average proportion of European admixture is only 7% [11].
If the risk for SLE varies with the proportion of the genome
that is of African origin, we would expect the risk ratio for
African-Americans compared with European-Americans to
be higher than the risk ratio for Afro-Caribbeans compared
with Europeans in the UK.
The only prevalence data from the Caribbean are from the
island of Curacao [12], where prevalence in adult women
was estimated to be 117 per 100000 during the period
1980–1989. This is likely to be an underestimate because
only a few cases were ascertained from outpatient clinics;
even so, it is far higher than the prevalence estimates for
women of European descent in the UK. Further evidence for
high rates of SLE in the Caribbean comes from the observa-
tion that in Birmingham, UK, most Caribbean-born patients
reported that their disease had begun before migration [6].
Although no other ethnic group has been found to have
such consistently high risk for SLE as people of west
African descent, there is some evidence of high risk in
people of Chinese descent who are settled outside China.
In a study in Malaysia [13], Chinese made up 81% of all
hospital admissions (to the only teaching hospital in west
Malaysia) with SLE, but only 35% of the local population.
A later study [14] estimated prevalence rates (per
100 000) as 46 in Chinese, 26 in Indians and 12 in
Malays. High rates in Malaysian Chinese when compared
with other ethnic groups might be partly explained by
greater access to health care. Excess prevalence of SLE
was also reported among Chinese-Americans in Hawaii,
however, where prevalence of SLE (per 100 000, both
sexes) was estimated to be 24 in Chinese, 20 in Polyne-
sians and six in Europeans [15]. Although these rates
were based on small numbers of cases, the differences
were statistically significant. These findings were sup-
ported by a subsequent study in Hawaii [16] in which age-
adjusted prevalence rates for SLE were 33 per 100 000 in
Chinese and 10 per 100 000 in Europeans (both sexes),
with cases ascertained from hospital records and death
certificates. The high risk in Polynesian islanders is consis-
tent with a study in New Zealand [17], in which preva-
lence per 100 000 (both sexes) was estimated to be 50 in
Polynesians compared with 15 in Europeans.
Role of known genetic associations in ethnic differences in
risk for systemic lupus erythematosus
Several loci have been identified at which variation is
associated with risk for SLE. In order to determine
whether the high risk for SLE in people of west African
descent compared with the risk in Europeans can be
accounted for by higher frequencies in west Africans of
alleles or haplotypes that have been associated with
increased risk for SLE within populations, we have calcu-
lated the population risk ratio (which is derived from the
risk ratio between the exposed groups under study, in this
case west Africans and Europeans) generated by each
locus. The population risk ratio is calculated as follows:
1 + pA(R–1)Population risk ratio = 
1+ pE(R–1)
where pA is the frequency of the high risk genotype in
Africans, pE is the frequency of the high risk genotype in
Europeans, and R is the risk ratio for the high risk geno-
type compared with the low risk genotype. This is based
on a simple risk assessment where genotypes are classi-
fied as either high or low risk.
This calculation provides the risk ratio between west
Africans and Europeans that we would predict from the
risk ratios between genotypes and the frequency of geno-
types in each population. For instance, if the frequency of
a high-risk genotype is 50% in west Africans and 0% in
Europeans, and this genotype is associated with a twofold
risk for disease, this doubled risk for disease in half the
west African population will generate a risk ratio of 1.5
between west Africans and Europeans. For each locus we
have collated whatever data are available on the risk ratios
associated with each genotype within populations and the
allele frequencies in west Africans and Europeans. The
results are summarized in Table 2.
Associations with variation in the human leucocyte antigen region
Most of the loci at which associations with risk for SLE
have been identified are in the HLA region. This region,
extending over about 4000 kilobases on chromosome 6,
contains the class I genes HLA-A, HLA-B and HLA-C, and
the class II gene families HLA-DP, HLA-DQ and HLA-DR.
When alleles were typed by their antigenic specificities,
the HLA-DR family of genes was considered as a single
locus and alleles were designated in the sequence (DR1,
DR2 ... DRw6, …) where the ‘w’ indicated a provisional or
‘workshop’ designation. Later five distinct genes (DRA,
DRB1–4) were identified within the HLA-DR family, and
their alleles were numbered (*0101, *0102, …) according
to their nucleotide sequences. In addition to the genes for
HLA antigens, the HLA region includes the genes for com-
plement proteins C2 and C4, the heat shock protein
HSP70-2 and tumour necrosis factor-α.
A difficulty in interpreting the associations with disease that
have been reported for genes in the HLA region is that in
this region there are strong associations between alleles at
nearby loci. This allelic association is termed ‘linkage dise-
quilibrium’ by geneticists. Association between alleles at
different loci is a consequence of their origin on the same
ancestral chromosomes. Linkage disequilibrium is com-
monly observed when two loci are so close together
(usually less than 1 million base-pairs) that this association
has not had time to decay through recombination.
Alleles at the C2 and C4 loci are in strong linkage disequi-
librium with alleles at other loci within the HLA region. SLE
in Europeans is associated with allele B8 at the HLA-B
locus [18], with allele *0501 at the DQA1 locus [19], with
alleles DR2 and DR3 at the HLA-DR locus [20,21], and
with the null allele at the C4A locus [20]. Risk ratios asso-
ciated with DR3 loci are generally similar in African-Ameri-
cans (2.7) to the risk ratios in Europeans (2.4). The
associations with SLE of B8 at the HLA-B locus and DR3
at the HLA-DR locus are no longer detectable when their
association with the null allele at the C4A locus is taken
into account [20,22,23], but the association of allele
*0501 at the DQA1 locus remains statistically significant
after controlling for presence of the C4A null allele [19].
The frequency of the C4A null allele is no higher in
African-Americans than in Europeans.
Family-based studies of transmission of haplotypes from
parents to affected offspring are required to establish
definitively which of these loci influence risk for SLE
directly, and which are associated with disease only
through linkage disequilibrium with other loci that influ-
ence risk directly. Table 1 shows that none of the alleles at
loci HLA-B, HLA-DR or C4A that are associated with SLE
are more common in west Africans than in Europeans.
A 28 base-pair deletion allele at the C2 locus is strongly
associated with SLE, but its frequency is so low (1% in
Europeans and zero in west Africans) that this mutation
does not contribute to the overall population risk ratio for
SLE [24]. The 8.5-kilobase-pair allele at the heat shock
protein HSP70-2 locus has been shown to be associated
with SLE in African Americans (independent of associations
with the null allele at the C4 locus or HLA-DR3) [25]. The
frequency of this allele is higher in Africans (0.6) than in
Europeans (0.4), but this could account only for a risk ratio
of 1.2 between west Africans and Europeans. The –308A
allele of the tumour necrosis factor-α gene is independently
associated with an increased risk for SLE in Europeans, but
the frequency of this allele is not higher in African Ameri-
cans (0.04) than it is in Europeans (0.12) [26,27].
Associations with loci outside the human leucocyte antigen
region
Mannose-binding protein is a serum protein that can acti-
vate complement. Variant alleles exist in which either
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Table 2
Extent to which known genetic associations can account for west African/European difference in risk for systemic lupus
erythematosus
Risk ratio Allele frequencies controls
Locus Alleles Eur Afr Eur Afr Population risk ratio*
Loci within the HLA region
HLA-DR [20,21,65] DRB1*0301 (DRw17) 2† 1.3† 0.12 0.14 1.0
DRB1*0302 (DRw18)
(HLA-DR2)
DRB1*1501 (DRw15) 2.4† 2.7† 0.13 0.14 1.0
DRB1*1503 (DRw15)
(HLA-DR3)
HLA-B [18] *0801 (B8) 1.8 1.4 0.12 0.03 0.9
C4A [20] *Q0 (Null) 3.0 3.6 0.1 0.07 0.9
TNF-α [27] –308A 3.8 2.7 0.12 0.04 0.9
HSP70-2 [25] 8.5-kilobase Pst1 2.1 2.6 0.36 0.61 1.2
Loci outside the HLA region
Mannose-binding protein (54) [28,66] GAC 1.6 1.4 0.19 0.11 1.0
FCγRIIa [29] R131 1.3 1.8 0.51 0.48 1.0
*The population risk ratio has been calculated using the mean of the genotypic risk ratio in Europeans and the genotypic risk ratio in Africans,
calculating genotype frequencies assuming Hardy–Weinberg equilibrium. †Risk ratios have been calculated by averaging frequencies of HLA-DR2
and HLA-DR3 across studies [21,65]. HLA, human leucocyte antigen; HSP, heat shock protein; TNF, tumour necrosis factor.
codon 54 or 57 of the mannose-binding protein gene is
altered, causing deficient complement activation. These
variant alleles are associated with SLE in both African and
European populations, with risk ratios of about 1.5. The
frequency of the codon 54-variant allele is lower (0.11) in
Africans than in Europeans (0.19) [28], however, so this
cannot account for higher risk in west Africans.
Allelic variants of FcγRIIa influence the ability to clear circu-
lating immune complexes, and have been associated with
risk for lupus nephritis in African-Americans and Europeans.
In a multicentre study of 214 SLE patients and 100 non-
SLE control-individuals the odds ratio for the risk for SLE in
FcγRIIA-H131/R131 heterozygotes and R131/R131 homo-
zygotes compared with H131/H131 homozygotes was 1.8
[29]. R131/R131 homozygotes and R131/H131 hetero-
zygotes are not more common in African populations (73%
compared with 76% in Europeans), and thus the higher risk
in African-Americans is not accounted for.
In summary, the higher risk for SLE in west Africans com-
pared with the risk in Europeans cannot be accounted for
by higher frequencies of high-risk alleles or haplotypes at
any of the loci at which variation is associated with risk for
SLE within populations.
Ethnic variation in risk for rheumatoid arthritis
Comparisons of RA prevalence in different populations are
difficult to interpret unless standardized methods are used.
Prevalence estimates depend on the methods used to ascer-
tain cases, whether point prevalence or period prevalence is
recorded, and whether ‘probable’ or only ‘definite’ cases are
included. The highest prevalence rates are obtained in
surveys that include radiographic screening of all individuals
sampled. The results are summarized in Table 3. Lower
prevalence rates are generally found in surveys that rely on a
two-stage screening process – questionnaire screening for
RA followed by radiographs of those who report symptoms.
The results are summarized in Table 4. Only two surveys of
the European-American population included radiographic
screening of the entire sample [30].
The highest prevalence rates of RA have been recorded in
Native American populations such as the Pima, Chippewa
http://arthritis-research.com/content/2/2/115
Table 4
Ethnic variation in prevalence of rheumatoid arthritis: studies using two-stage screening
Prevalence/1000
Ethnic origin Location Age (years) Males Females Both
Pima Arizona, USA [31] >20 10 31
Yakima Washington, USA [33] 18–79 N/A 34
European Minnesota, USA [35] 35–85 7.4 14
European and Afro-American NHANES, USA [30] 18–79 6 15
European Manchester, UK [36] 45–65 8
Afro-Caribbean Manchester, UK [36] 44–66 2.9
NHANES, National Health and Nutrition Examination Survey.
Table 3
Ethnic variation in prevalence of rheumatoid arthritis: studies using radiography for primary screening
Prevalence/1000
Ethnicity Location Age range (years) Criteria Males Females
Chippewa Native American Minnesota, USA [34] >18 ACR 48 59
Pima Native American Arizona, USA [32] >30 ARA* 50 60
Pima Native American Arizona, USA [63] >20 ARA 32 70
Afro-American NHES, USA [37] 18–79 ARA* 7 16
European-American NHES, USA [37] 18–79 ARA* 7 16
European-American Sudbury, USA [64] 15–75 ARA* 5 15
ARA* refers to diagnosis based on modified ARA criteria. ACR, American College of Rheumatology; ARA, American Rheumatism Association;
NHES, National Health Examination Survey.
and Yakima tribes [30–34]. In surveys based on radio-
graphic screening of the entire population, prevalence in
adults from these populations has been estimated to be in
the range 32–48 per 1000 for men and 59–70 per 1000
for women. By comparison, in the National Health Exami-
nation Survey conducted from 1960 to 1962, using bilat-
eral hand and foot radiographs and serologic tests for
rheumatoid factor, RA prevalence in the general US popu-
lation aged 18–79 years was estimated at 7 per 1000 in
men and 16 per 1000 in women.
Lower prevalence rates have been recorded in surveys
that have used a two-stage screening process: 31–34 per
1000 in Native American women [33]. In that study the
case definition was more restrictive than in other studies.
For comparison, in European-Americans and African-
Americans, surveys using a two-stage screening process
have yielded prevalence rates of 6–7 per 1000 in men
and 14–15 per 1000 in women [30,35].
There is no consistent evidence that any other ethnic
group apart from Native Americans is at unusually high
or low risk for RA. Although people of Afro-Caribbean
origin (mainly first-generation and second-generation
migrants) in the UK appear to have a lower prevalence of
RA compared with that in the general population [36], in
the USA the prevalence of RA is similar in African-Ameri-
cans and European-Americans [30,37]. In South Africa,
prevalence of RA in urban African populations has been
estimated to be around 10 per 1000 (both sexes com-
bined), which is similar to the estimates for populations
of European descent [38]. However, prevalence of RA in
rural South African populations was noted to be signifi-
cantly lower than in urban populations (0.87% compared
with 3.3%, respectively), suggesting that environmental
factors play an important role that would explain such
marked differences in genetically closely related commu-
nities [39].
Prevalence surveys of Chinese populations in native China
[40] and Hong Kong [41], using a two-stage screening
protocol with questionnaires and radiographs of all those
with symptoms, have found prevalence of RA to be lower
(around 5 per 1000 in women) than that in comparable
surveys of populations of European descent. It is possible
that some patients may have been overlooked who did not
qualify for radiographic examination. There are no surveys
of prevalence of RA in Chinese Americans that can be
compared with rates in Europeans.
Other rheumatic conditions such as ankylosing spondylitis
appear also to be commoner in Native Americans than in
Europeans. Using four different subsamples of Native
American adult males aged over 25 years, the prevalence
of sacro-iliitis grade 2 or more on radiography (based on
Rome 1962 criteria) was estimated at 100 per 1000 [42].
This compares with a prevalence of about 10 per 1000 in
men from the general US population.
Studies that compared the sequences of HLA antigens
have pointed to a direct effect of variation at the HLA-
DRB1 locus on susceptibility to RA [43]. At this locus all of
the alleles that are associated with high risk for RA share
an identical amino acid sequence in positions 70–74: the
‘shared epitope’ [44]. These alleles include *0101
(included in DR1), *0401/*0404/*0405/*0408 (included in
DR4), *1001 (DRw10), *1402 (included in DRw14) and
*1601/*1602 (DRw16) [45–48]. Although others have
concluded that the high risk for RA in Native Americans
compared with Europeans can be largely explained by the
higher frequency of shared epitope alleles in Native Ameri-
cans, this interpretation has not been supported by calcula-
tion of the population risk ratio. In Europeans the total
frequency of ‘shared epitope’ alleles is about 25%, mainly
alleles *0101, *0401 and *0404. Thus, approximately 44%
of Europeans have at least one copy of a ‘shared epitope’
allele. In Native Americans about 82% have at least one
copy of allele *1402 [48], from which the allele frequency
can be estimated as 0.58. The frequency of other ‘shared
epitope’ alleles in Native Americans is about 0.04 [49], and
thus approximately 86% of Native Americans have at least
one copy of a ‘shared epitope’ allele. In both Europeans
and Native Americans, the risk ratio for RA associated with
the presence of at least one copy of a ‘shared epitope’
allele is about 2.7 [45,48]. On this basis, we can calculate
the population risk ratio generated by the HLA-B1 locus to
be about 1.4 in Native Americans compared with that in
Europeans. This accounts for only a small fraction of the
observed risk ratios of approximately 4 between these two
groups.
Relation of European admixture to rheumatic
disease
As a result of maritime expansion during the past 500
years, admixture between populations that were previously
isolated from one another has occurred on a large scale in
many parts of the world. Where ethnic differences in
disease risk have been observed and admixture between
high-risk and low-risk ethnic groups has occurred, studies
of these admixed populations can help to advance under-
standing of the aetiology of disease in several ways. First,
studying the relationship of disease risk to the proportion-
ate admixture of individuals can help to distinguish
between genetic and environmental explanations for the
ethnic difference in disease risk. Second, studying the
form of the relationship can yield information about the
underlying genetic model. Finally, where a relationship of
disease risk to admixture has been identified, it is possible
in principle to exploit recent admixture to map the genes
that underlie this relationship in a manner that is analogous
to linkage analysis of an experimental cross [50,51]. In
order to estimate the proportionate admixture of individu-
Arthritis Research    Vol 2 No 2 Molokhia and McKeigue
als, it is necessary to type large numbers of markers that
are highly informative for ancestry. Until recently such
markers have not been available.
Admixture as a confounder of genetic associations
In most genetic study designs, admixture is considered as
a nuisance variable because variation in individual admix-
ture (‘hidden population stratification’) can generate asso-
ciations of alleles at marker loci with disease even though
the marker locus is not linked to any gene that influences
disease risk. In an admixed population, any trait that is
present at higher frequency in an ethnic group will show
positive association with any allele that happens to be
common in that group [52]. For example, risk for type 2
(noninsulin-dependent) diabetes is far higher in Pima
Native Americans than in Europeans. In the Pima popula-
tion, the presence of haplotype Gm3;5,13,14 is inversely
associated with diabetes [53]. This association arises not
because the Gm locus is linked to diabetes, but because
haplotype Gm3;5,13,14 is more common in Europeans (fre-
quency 0.67) than in unadmixed Native Americans (fre-
quency 0.01), and the proportion of European ancestry
varies within the Pima population. The inverse relation of
risk for diabetes to the proportion of European admixture
within this population leads to inverse associations of dia-
betes with markers of European admixture, such as haplo-
type Gm3;5,13,14.
In an epidemiological study, a confounder is a factor that
is associated with the exposure under study and is inde-
pendently associated with disease risk. In this sense,
admixture is a confounder because it is associated with
the ‘exposure’ under study (an allele at the marker locus)
and independently associated with disease risk. Thus, for
instance, an association between allele Dw16 at the HLA-
DRB locus and RA in Mexican-Americans could arise
simply because allele Dw16 is more common in those with
a higher proportion of Native American ancestry.
To eliminate this confounding by admixture, one possible
strategy is to control for admixture in the design by typing
parents of cases, and using the two untransmitted parental
alleles as controls for the two alleles transmitted to each
affected individual. This is a ‘family-based’ association study
design [54]. An alternative, when parents of patients are not
available, is to control for admixture in the analysis. For this it
is necessary to type cases and controls for a set of markers
that have different allele freqencies in the two (or more)
ancestral populations, and are unlinked to the locus under
study. The association can then be adjusted either by esti-
mating admixture directly from the observed marker data, or
indirectly by using the marker data to derive a measure of
genetic distance between cases and controls [55]. An
extension of this approach would be to establish whether,
for instance, the difference in risk for RA between Native
Americans and Europeans can be accounted for by the
HLA region. For this one could study cases and controls
from the Mexican-American population, within which the
proportion of Native American admixture varies widely. By
typing multiple markers within the HLA region, the ancestry
of the HLA-DRB locus could be assigned as 0, 1 or 2
alleles of Native American ancestry. Estimating the strength
of association between RA and the proportion of Native
American ancestry after adjusting for ancestry at the HLA-
DRB locus would yield an estimate of the risk ratio between
the two populations that is not explained by this locus.
Relationship of disease risk to admixture
Within an admixed population, ancestry of the genome will
vary between individuals. This variation in individual admix-
ture can be maintained by continuing gene flow from the
ancestral populations or by social stratification, as in
Mexican-Americans in whom socioeconomic status is
related to the proportion of European ancestry [56]. If the
ancestral populations differ in risk for disease, and this dif-
ference in risk has a genetic basis, we can predict that
within the admixed population there will be a relationship
between admixture and disease risk. If, for instance, the
higher risk for SLE in west Africans compared with the risk
in Europeans results from higher frequencies in west
Africans of alleles (at one or more loci) that increase the
risk for SLE, then within a population of mixed west
African/European descent risk will vary with the proportion
of the genome that is of African ancestry. There will there-
fore be a linear relationship between risk for SLE and the
number of alleles (0, 1 or 2 alleles) that have African ances-
try at one of the disease loci. In the language of statistical
genetics this is an ‘additive’ model, in the sense that addi-
tive effects account for most of the genetic variance.
In order to understand how genetic effects on a trait are
partitioned into ‘additive’ and ‘dominant’ effects, we can
imagine that the risk for disease is plotted against the
number of copies of the high risk allele (0, 1 or 2) that
make up the genotype. This will give a graph with three
points, weighted by the frequencies with which the three
genotypes occur in the population. The additive variance
attributable to the locus is the variance accounted for by a
regression line fitted to these three points. The dominance
variance attributable to the locus is the residual variance
(variance about the regression line) in this regression
model. If the regression line fits the three data points per-
fectly (linear relationship of disease risk to number of
copies of the high risk allele), there is no dominance vari-
ance and all of the genetic variance attributable to the
locus is accounted for by additive effects [57].
An alternative genetic model for the high risk for SLE in
African-American and Afro-Caribbean populations could
be that admixture itself leads to increased risk. Admixture
between two populations that have different allele fre-
quencies at a locus leads to an increase in heterozygosity
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(the proportion of individuals who are heterozygous) at
this locus, in comparison with the average heterozygosity
of the two populations between which this admixture
occurred. To take an extreme example, at the FY (Duffy
blood group) locus, the frequency of the null allele is 0 in
Europeans and 1 in west Africans [11]. The proportion of
individuals who are heterozygous is 0 in unadmixed Euro-
peans and 0 in west Africans, and can be calculated from
the Hardy–Weinberg theorem as 32% (2 × 0.20 × 0.80)
in an homogenous African-American population in which
20% of the genome is of European ancestry.
If the risk for SLE is higher in individuals who are heterozy-
gous at one or more loci that controls immune function than
in individuals who are homozygous at these loci, the risk will
be higher in people of mixed west African/European
descent than in unadmixed west Africans and unadmixed
Europeans. The highest risk would be in the first generation
of mixed descent (equivalent to the F1 generation in an
experimental cross), who have one African and one Euro-
pean allele at each locus. In statistical terms this would be
an ‘overdominant’ model in that dominance effects account
for most of the genetic variance [57]. An experimental
model for this is the cross between New Zealand Black and
New Zealand White strains of mice. In offspring that have
one parent from each of these two strains, the risk for lupus
is higher than in either of the two original inbred strains [58].
Because human ethnic groups are not inbred strains, the
effect of admixture on heterozygosity is likely to be small
except at a few loci where different alleles have been fixed
in Europeans and west Africans.
Recent studies have shown that the average proportion of
European admixture in African-Americans is lower than
previously estimated (14–22% in most of the populations
studied) and varies only over a narrow range [11]. This
narrow range of variation in individual admixture means
that studies of the relationship of disease risk to individual
admixture in African-American populations have low statis-
tical power. Other populations may exist, for instance in
the Caribbean, where admixture varies over a wider range.
As yet there has been only one study on the relation of
SLE to admixture in humans [59]. Seventy-two cases and
79 controls were sampled from the African-American pop-
ulation of Baltimore. The average proportion of European
admixture, estimated by typing classical protein polymor-
phisms (blood groups, erythrocyte enzymes and serum
proteins), was estimated to be the same (29%) in cases
and controls. The markers used were not specified. To
estimate individual admixture accurately would require at
least 40 markers, and to estimate the slope of the relation-
ship of disease risk to admixture accurately would require
larger numbers of cases and controls.
The only study to examine the relation of RA to admixture
was a case–control study in African-Americans [60]. Eigh-
teen African-American probands with RA and 15 non-RA
families were studied. Extended haplotypes of European
ancestry were more common in the cases than in the con-
trols, even though haplotypes of European ancestry that
were known to be associated with RA had been excluded
from the analysis. The interpretation of this result depends
on whether this association with alleles of European ances-
try is specific to the HLA region (implying that haplotypes
in this region that are more common in Europeans predis-
pose to RA) or whether it is present over the entire genome
(implying that other unidentified loci underlie the associa-
tion of RA with European ancestry in African-Americans).
There are no studies of the relationship of RA risk to Euro-
pean admixture in people of mixed European/Native Amer-
ican descent. The Mexican-American population of the
USA is of mixed European/Native American descent, and
the proportion of Native American ancestry is related to
socioeconomic status. In a case–control study in Mexican
Americans [61], the associations between RA and HLA-
DRB1 alleles containing the shared epitope sequence
were of similar magnitude to those in Europeans. No
attempt was made to control for the proportion of Native
American admixture, however, so that it is not possible to
establish whether the association was specifically with the
shared epitope, or more generally with the proportion of
Native American ancestry.
Mapping genes underlying ethnic differences
in disease risk
Allele-sharing and association studies
Current attempts to map genes that influence rheumatic
diseases are based on two main approaches: analysis of
identity-by-descent sharing (‘allele-sharing studies’) in fam-
ilies with multiple affected members, or association
studies of polymorphisms in candidate genes [62]. Both
approaches have limitations. Allele-sharing studies lack
adequate power to detect genes of modest effect. Unless
a single locus accounts for a sibling recurrence risk ratio
of 2 or more [62], very large numbers of families are
required for adequate power to detect this locus and map
it to a small region of the genome. Association studies
have far greater statistical power than allele-sharing
studies, but depend on knowing which gene to look at.
Genome-wide association studies may eventually become
possible, but will require the ability to type more than
100 000 marker polymorphisms in each individual studied.
Study designs that exploit admixture to map genes
A far more powerful method for mapping genes for
complex traits is available to experimental geneticists, who
detect linkage by studying hybrid populations formed by
crossing two inbred strains that differ in the trait under
study. The genomic regions that contain loci that underlie
this difference in the trait can be detected by testing for
association of the trait with inheritance of marker alleles
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from the strain that has higher trait values. The same princi-
ple can be applied in humans to detecting genes that
underlie ethnic differences in disease risk, by studying pop-
ulations formed by admixture between a high-risk and a
low-risk population. Figure 1 shows, for a pair of chromo-
somes in an F2 sibship of mixed European/African descent,
how crossing two ancestral strains generates variation in
states of ancestry in the F2 and subsequent generations. In
the second (F2) and subsequent generations of mixed
descent, ancestry on chromosomes varies between two
states, European and African, so that at any given locus an
individual of mixed descent may have 0, 1 or 2 alleles of
African ancestry. On chromosomes of mixed descent, the
states of ancestry at two linked loci will be correlated with
each other, because markers are likely to be inherited
together if they are near each other on the chromosome.
The more tightly linked the two loci are, the higher will be
the correlation. This autocorrelation of states of ancestry on
chromosomes inherited from parents of mixed descent
conveys information about linkage, and can be used to
map disease genes. Suppose, for instance that a disease
locus accounts for a risk ratio of 3 for SLE in west Africans
compared with Europeans. Within a population of mixed
west African/European descent, the risk for SLE will be
three times higher in those with 2 alleles of African ances-
try at the disease locus than in those with 0 alleles of
African ancestry at this locus, with other factors held con-
stant. In practice the most efficient design is to study only
affected individuals, and to test for regions of the genome
where the proportion of alleles that have African ancestry is
higher than expected. By comparing the observed propor-
tion of alleles at the marker locus that have African ancestry
with the expected proportion given the admixture of each
individual’s parents, association with the ancestry of alleles
at loci unlinked to the disease is eliminated [51]. The analy-
sis does not require parents to be available for typing,
because the admixture of an individual’s parents can be
estimated by typing markers in that individual.
Experimental crosses are generally conducted with inbred
strains, so that, in order to assign ancestry at all points on
the genome in a hybrid individual, it is sufficient to type
markers at loci where different alleles have become fixed
in each of the two parental strains. Because human ethnic
groups are not inbred strains, marker loci at which differ-
ent alleles have become fixed in each of the two founding
populations are rare. Thus, the information conveyed by
typing a single marker will not usually be sufficient to
assign the ancestry of each allele at the marker locus to
one of the two founding populations. This problem can be
overcome by using a multipoint statistical method to
combine information from all markers to estimate ancestry
at each locus [51]. Although advanced statistical methods
are required to apply this approach in practice, the under-
lying principles on which it relies to detect linkage are
simple. For example, to estimate ancestry at each locus in
a population of mixed European/west African descent, one
would first choose a set of marker polymorphisms that
have large differences in allele frequencies between Euro-
pean and Africans, spacing these markers at much higher
density than the transitions of ancestry that occur on the
chromosomes of individuals of mixed descent. If we type
these markers in an individual together with this individu-
al’s parents, siblings or offspring, we can assign haplo-
types and reconstruct the sequence of marker alleles on
each chromosome. Over any short interval, a haplotype in
an individual of mixed descent will be effectively unique to
one of the two founding populations. By combining infor-
mation from these marker alleles, we can reduce the
uncertainty with which ancestry at each locus is assigned
as 0, 1 or 2 alleles African by descent. This approach, in
which information about ancestry on chromosomes of
mixed descent is extracted from marker genotypes, differs
fundamentally from conventional linkage disequilibrium
mapping, which relies on detecting allelic association. By
combining information from all markers simultaneously in a
multipoint analysis, it is possible to extract all of the infor-
mation about linkage that is generated by admixture, which
is not possible in a conventional allelic association study
unless the markers are perfectly informative for ancestry.
The advantage of this approach is that, in comparison with
allele-sharing designs, study designs that exploit admixture
have far greater statistical power to detect genes of
modest effect if these genes contribute to the ethnic dif-
ference in disease risk. There are fundamental statistical
reasons for this [52]; allele-sharing designs rely on an indi-
rect comparison (allele-sharing in concordant pairs higher
than expected), whereas linkage analysis of a cross relies
on a direct comparison (risk for disease in those with 0, 1
or 2 alleles with ancestry from the high-risk strain).
Application of this approach in practice will require special
sets of markers for genome-wide assignment of ancestry:
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Figure 1
How hybridization gives rise to variation in ancestry on chromosomes
of mixed descent. Chromosomal segments of European and African
descent are represented by broken lines and continuous lines,
respectively.
African versus European ancestry for studies of SLE, and
Native American versus European ancestry for studies of
RA. Simulations indicate that for each pair of ancestral
populations, a set of about 1000 markers that have large
differences in allele frequency (>0.6) between the two
populations will be sufficient for a genome search [51].
Several possible strategies for assembling such markers
are available: screening libraries of microsatellite of single
nucleotide polymorphism (SNP) marker loci to identify
those that have large differences in allele frequencies;
using representational difference analysis (a subtractive
hybridization technique) to generate base sequences that
are common in one population but absent in another; and
screening multiple SNPs in candidate genes to define
intragenic haplotypes that are informative for ancestry.
With the availability of large public repositories of SNP
markers, identifying a subset of markers that are informa-
tive for ancestry will become easier.
Conclusion
The possibilities for exploiting admixture to investigate the
aetiology of rheumatic disease have not been fully
explored. Studies of how the risk for disease varies with
individual admixture could help to distinguish between
possible genetic models for the high risk for SLE in people
of west African descent and the high risk for RA in Native
Americans. Further studies in which markers are used to
assign ancestry in regions of interest, or across the entire
genome, could help to map, and eventually identify genes
that underlie these ethnic differences in risk for rheumatic
disease.
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